Median Technologies : Corporate Update – May 2024

Corporate Update

JEAN-CHRISTOPHE MONTIGNY, CFO MEDIAN TECHNOLOGIES

MAY 2024

Applying AI and computer vision, we help conquer cancer and other life-threatening diseases by extracting powerful clinical insights from medical images.

Our people	260+ highly qualified professionals in the
	US, Europe and China, 25+ nationalities
	(As of Dec. 31, 2023).
Our growth	Powered by proprietary AI, computer
	vision and signal processing technologies,
	strong KOL connections, and medical,
	scientific, technology partnerships.
	With eyonis , our AI/ML tech-based
	suite of software as medical devices
	(SaMD), we help enable clinicians to
	diagnose patients earlier.
Imaging	Our iCRO imaging solutions and advanced
Lab	Imaging Lab offer help our 80+
	biopharma clients drive their oncology
	clinical studies toward successful
	approval, using AI-driven image insights.

The Global Cancer Burden

Imaging AI will have the biggest impact ever on cancer care

3	mediantechnologies.com | May 2024 | Financial Conferences | Paris, France

Facts & Trends about Cancer

Financial burden of

1 cancer in the US was $210bn in 2020 and projected to exceed $245bn by 2030 [1].

The cost for bringing a

4 cancer drug to market is $2.7Bn [2] during 12 years. With AI it could be a fraction of the cost & time

97% of cancer care

2 money goes for treatment of sick patients vs 3% for preventive care.

5	The cost of developing a
new AI based imaging

diagnostic test for cancer is approx. $40m.

3

6

Most Stage 1 cancer can be cured and can now be identified with Imaging AI.

Most cancer drugs could become curative through personalized treatments. Viral Therapy, vaccine & immune therapy

		Sources:
		[1]	American Association for Cancer Research
4	mediantechnologies.com | May 2024 | Financial Conferences | Paris, France	[2]	Deloitte Report - January 2023

US Cancer Death Rates Evolution over the Long-run

Early diagnosis and lifestyles changes have the biggest impact on cancer death rates:

• Lung and stomach cancer death rates decrease, driven by lifestyles changes.

• Prostate, colorectal and breast cancer rates decrease, driven by early diagnosis and screening programs.

5 mediantechnologies.com | May 2024 | Financial Conferences | Paris, France

AI Breakthroughs Applied to Medical Imaging Mark the Beginning of a New Era for Cancer Management

Applying AI and computer vision technologies help conquer cancer by extracting powerful clinical insights from medical images.

1|	2|	3|	Guide health
professionals in
Diagnose			their clinical
cancer earlier		Personalize
	decision-making
and more		treatments
	with data-

accurately	driven clinical
	insights

6	mediantechnologies.com | May 2024 | Financial Conferences | Paris, France

Median Technologies Leverages AI Technologies to Bring More Value to Medical Images all along the Patient Journey

Adding more	Generating more	Providing more
AI-driven data
value to oncology	accurate
for oncology
trials	AI-driven diagnosis
drug development

•	Extract drug efficacy data	•	Select early-stage patient		•	Develop noninvasive, early-
•	Streamline the clinical	•	Discover predictive			stage diagnostic solutions
	process		imaging biomarkers		•	Market SaMDs for routine
							clinical use
						•	Develop companion diagnostics

7	mediantechnologies.com | May 2024 | Financial Conferences | Paris, France

Shifting the Early Diagnostic Paradigm with Artificial Intelligence

We are developing the next generation AI/ML tech-based Software as Medical Devices (SaMD) to help detect, diagnose and monitor early-stage cancer patients.

8	mediantechnologies.com | May 2024 | Financial Conferences | Paris, France

eyonis Integration in the Radiology Workflow

9	mediantechnologies.com | May 2024 | Financial Conferences | Paris, France

Lung Cancer Screening

I-ELCAP study showed a 92% survival rate at 15y when diagnosed at stage 1 vs. 5% for stage 4 (1) Lack of diagnosis accuracy is a major hurdle to screening adherence & programs implementation

Facts & Figures

• 1st cancer killer worldwide - 18% of all 2020 cancer deaths, equal to colorectal & liver cancers combined (2)
• 1.8M deaths in 2020, 2.4M projected in
  2030 (2)
• A new CPT reimbursement code of $650 for quantitative CT tissue characterization in the US
• The Lung Cancer Screening TAM is $10- 20bn for the US & EU and could double with Asia
• Rising frequency among never-smokers, 20% in the US & UK (3)
• Only 870K screenings performed in the US in 2021 - 6% compliance (4)

10 mediantechnologies.com | May 2024 | Financial Conferences | Paris, France

Target Population

	LCS Programs	Target population
US	Implemented - USPSTF	19M (USPSTF, 2023
guidelines	recommendations)
	Implemented in Croatia
Europe	& Poland - Starting in UK	EU T5: 22M (Est.)
- Developing in
	IT/FR/GE/SP/NL/SW
	Implemented in SK
Asia	nationally & China	ASIA T3: 100M
regionally - Japan/Taiwan	(Est.)
	study phase

Sources:

1. https://www.redjournal.org/article/S0360-3016(19)30110-5/fulltext
2. Cancer Tomorrow, IARC, Global Cancer Observatory 2020 - WHO
3. https://www.lungambitionalliance.com/our-initiatives/lung-cancer-screening-the-cost-of-inaction.htm
4. https://nrdrsupport.acr.org/support/solutions/articles/11000093991-lcsr-state-reports